Which patients with myelofibrosis should receive ruxolitinib therapy? ELN-SIE evidence-based recommendations

M. Marchetti, G. Barosi, F. Cervantes, G. Birgegård, M. Griesshammer, C. Harrison, R. Hehlmann, J. J. Kiladjian, N. Kröger, M. F. McMullin, F. Passamonti, A. Vannucchi, T. Barbui

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'Which patients with myelofibrosis should receive ruxolitinib therapy? ELN-SIE evidence-based recommendations'. Together they form a unique fingerprint.

Medicine & Life Sciences